Team Leader:



© Croix du Nord / Cécile Huyghe

Dr Chamaillard graduated his PhD in 2002 and has been appointed as a Research Director at Inserm in 2011 (H-index = 32 and 11,447 times cited without self-citations). At the Fondation Jean Dausset, he pionnered our understanding of the underlying mechanisms that are predisposing to inflammmatory bowel diseases by contributing to the identification of NOD2 as the major Crohn's disease predisposing gene (Nature 2001) and then moved to the laboratory of Professor Gabriel Nunez at the University of Michigan to further elucidate the function of the NOD2 gene (EMBO J 2003 and Science 2005) and of its closest related molecule NOD1 (Nature Immunology 2003). Dr Chamaillard received several awards, including the Crohn's and Colitis Foundation of America Young Investigator Award in 2004 and the UEP Top Abstract Prize, and he has has been invited to several international meetings, including Keystone symposium, FALK symposium, European Immunology Group Meeting and International Congress of Mucosal Immunology.


The Chamaillard's laboratory on Nods-like receptors in infection and immunity is interested in defining how Nods-like receptors contribute to microbial tolerance, host defence and antitumoral immunity, and how deregulation of several Nods-like receptors (including the Crohn's disease predisposing NOD2 gene) break down in Crohn's disease and colitis-associated colorectal cancer. Crohn's disease affects millions of individuals worldwide through the influence of several genetic and environmental factors. While a disproportionate immune response is found in Crohn's disease patients, our most recent studies in mice experimentally demonstrated that defects in the Crohn's disease predisposing NOD2 gene alters the functionality of the gut microbiome in a manner that it disrupts intestinal homeostasis and confers a risk of colitis and intestinal tumorigenesis (J Clin Invest, 2013).

Using a variety of techniques and complex genetic models, we have contributed to the field of mucosal immunology by identifying novel dendritic cell subsets and several pathways that underlie inflammation-driven carcinogenesis. Notably, Lionel F. Poulin contributed to a better understanding of mouse and human dendritic cells by the identification and characterization of a novel subset of dendritic cells that is involved in the generation of cytotoxic CD8+ T cells in mice and human (JEM 2007, JEM 2010, JEM 2010). Meanwhile, the laboratory has also unveiled several mechanisms that are contributing to the efficacy of the wound healing process (Proc Natl Acad Sci U S A 2011, Gut 2013, Proc Natl Acad Sci U S A 2013) and how cigarette smoking may modulate risk of developping Crohn's disease (Gastroenterology 2017). Foremost, we recently unveiled an unexpected role of Nod2 on anti-cancer drugs efficacy as an epithelial-operating immune checkpoint (Immunity 2016).

The Chamaillard's laboratory was created in 2010 with the highest possible grade (A+) by the French national research assessment agency and with an uninterrupted funding record since 2004. During the last five years, our laboratory was labelled as Equipe Fondation pour la Recherche Médicale. Since then, about 80 papers were published in peer-reviewed international journals in the field of immunology, gastroenterology and oncology, which includes about 20 cutting-edges original articles (eg. Blood Gastroenterology, Gut, Immunity, J Clin Invest, J Exp Med, Nature Medicine, Proc Natl Acad Sci U S A, Science).